147 results
20-F/A
2006 FY
REPCF
Replicel Life Sciences Inc.
7 Sep 07
Annual report (foreign) (amended)
12:00am
information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, the NASD … in substantial costs for our company and a diversion of management's attention and resources.
United States investors could suffer adverse tax consequences if we
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
3 Aug 20
Consolidated Financial Statements
12:00am
. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax determination is uncertain … . The Company recognizes liabilities and contingencies for anticipated tax audit issues based on the Company's current understanding of the tax law
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
22 Dec 20
Current report (foreign)
3:05pm
the provision for income taxes. There are many transactions and calculations undertaken during the ordinary course of business for which the ultimate tax … determination is uncertain. The Company recognizes liabilities and contingencies for anticipated tax audit issues based on the Company's current
20-F/A
uk339izee3or9k79
12 Sep 22
Annual report (foreign) (amended)
6:17pm
6-K
EX-99.1
uu3vpuqre
15 Oct 20
Condensed Consolidated Interim Financial Statements
5:15pm
20-F/A
r7lmnpsazdva6
3 Jul 08
Annual report (foreign) (amended)
12:00am
6-K
EX-99.1
57s7lu96z6j 0g5uyw
30 Nov 20
Condensed Consolidated Interim Financial Statements
5:19pm